$1B deal for SiranBio’s oligonucleotide candidate

Cardiometabolic disease is the leading cause of death in approximately 50% of patients with chronic kidney and liver diseases. Growing evidence links visceral adipose tissue to cardiometabolic risk and lowering this in people with chronic inflammatory diseases could have a greater impact on their survival than managing the underlying disease alone. SiranBio’s SA030 targets ALK7, an established mechanism for addressing cardiometabolic disease, which could reduce visceral adipose tissue, while preserving lean mass, leading to improved insulin sensitivity, blood lipid profile and reduced fat cell-driven inflammation.

Preclinical studies have shown a differentiated, long-acting profile for SA030 that could address the underlying inflammation associated with cardiometabolic risk through adipocyte-directed delivery and a low-frequency dosing schedule. SA030 has a complementary and distinct mechanism to GLP- 1 agonists and SGLT2 inhibitors, supporting potential future combination approaches to lower remaining cardiometabolic risk not fully addressed by current therapies.

“We are very honoured to be recognized by a top biopharma company for our cutting-edge extrahepatic delivery technology and siRNA pipeline,” explained Zhiwei Yang, SiranBio Founder and CEO. “GSK’s resources and clinical development capabilities have the potential to accelerate the transformation of our innovative pipeline into therapeutics, benefitting more people in the reduction of fat and related chronic diseases.”

SA030 will benefit from GSK’s extensive expertise in oligonucleotide therapeutics, such as siRNA and antisense oligonucleotides, a key modality that could address therapeutic targets, including ALK7, that are not amenable to traditional small molecules or biologics.